{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T18:16:43Z","timestamp":1788373003375,"version":"build-2803163510"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010663","name":"H2020 European Research Council","doi-asserted-by":"publisher","award":["787270"],"award-info":[{"award-number":["787270"]}],"id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Raised levels of serum interleukin 6 (IL-6) have been found in some studies of Paget\u2019s disease of bone (PDB), and this cytokine has been suggested to act as a mediator of increased osteoclast activity in the disease. Here weevaluated serum IL-6 in two cohorts of patients with PDB and controls and related serum IL-6 levels in PDB patients to clinical features of the disease. Serum IL-6 was measured by ELISA in 553 individuals with PDB from the PIP study (n\u00a0=\u00a0\u2009165), the PRISM study (n\u00a0=\u00a0388) and 533 population-based controls. In the PDB cases, we studied associations between IL-6 and disease extent, pain, previous bisphosphonate therapy, and biochemical markers of bone turnover. Serum IL-6 was correlated with age (r\u00a0=\u00a00.256,\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0&lt;\u00a00.001) and serum creatinine (rho = 0.148,\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0&lt;\u00a00.001) but values did not differ in males and females. Following adjustment for age and serum creatinine, there was no significant difference in IL-6 between PIP cases and controls (\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a00.268) or PRISM cases and controls (\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0=\u00a00.399) nor was there a significant correlation between serum IL-6 and number of affected bones in PDB or bodily pain. Serum IL-6 was correlated with total alkaline phosphatase (rho\u00a0=\u00a00.174,\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0&lt;\u00a00.001), and PINP (rho\u00a0=\u00a00.095,\n                    <jats:italic>p<\/jats:italic>\n                    \u00a0&lt;\u00a00.05) but not with the bone resorption marker CTX. In summary, we found no difference between circulating IL-6 values in PDB and controls but serum IL-6 was related to alkaline phosphatase and PINP. These observations do not support a role for raised circulating IL-6 values as an important driver of osteoclast activity in PDB.\n                  <\/jats:p>","DOI":"10.1007\/s00223-026-01595-7","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:45:28Z","timestamp":1788371128000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of the Role of Interleukin 6 in Paget\u2019s Disease of Bone"],"prefix":"10.1007","volume":"117","author":[{"given":"Kathryn","family":"Berg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katya","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James F.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C. Y.","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2804-7586","authenticated-orcid":false,"given":"Stuart H.","family":"Ralston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,2]]},"reference":[{"key":"1595_CR1","doi-asserted-by":"publisher","DOI":"10.1093\/ejendo\/lvaf202","author":"SH Ralston","year":"2025","unstructured":"Ralston SH (2025) Latest developments in Paget\u2019s disease of bone. Eur J Endocrinol. https:\/\/doi.org\/10.1093\/ejendo\/lvaf202","journal-title":"Eur J Endocrinol"},{"key":"1595_CR2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab232","author":"MJ Cook","year":"2021","unstructured":"Cook MJ, Pye SR, Lunt M, Dixon WG, Ashcroft DM, O\u2019Neill TW (2021) Incidence of Paget\u2019s disease of bone in the UK: evidence of a continuing decline. Rheumatology. https:\/\/doi.org\/10.1093\/rheumatology\/keab232","journal-title":"Rheumatology"},{"key":"1595_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaf280","author":"C Rebollo-Najera","year":"2025","unstructured":"Rebollo-Najera C, Usategui-Martin R, Lobato-Carrasco J, Gil-Gonzalez MD, Miron-Canelo JA, Miramontes-Gonzalez P, Ralston SH, Corral-Gudino L (2025) Continuous decline in Paget\u2019s disease of bone: a one health perspective on 2342 new diagnoses and their association with rural livestock. Rheumatology. https:\/\/doi.org\/10.1093\/rheumatology\/keaf280","journal-title":"Rheumatology"},{"key":"1595_CR4","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1007\/s00223-004-0281-z","volume":"75","author":"HR Cundy","year":"2004","unstructured":"Cundy HR, Gamble G, Wattie D, Rutland M, Cundy T (2004) Paget\u2019s disease of bone in New Zealand: continued decline in disease severity. Calcif Tissue Int 75:358\u2013364. https:\/\/doi.org\/10.1007\/s00223-004-0281-z","journal-title":"Calcif Tissue Int"},{"key":"1595_CR5","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1359\/jbmr.061108","volume":"22","author":"D Naot","year":"2007","unstructured":"Naot D, Bava U, Matthews B, Callon KE, Gamble GD, Black M, Song S, Pitto RP, Cundy T, Cornish J, Reid IR (2007) Differential gene expression in cultured osteoblasts and bone marrow stromal cells from patients with Paget\u2019s disease of bone. J Bone Miner Res 22:298\u2013309","journal-title":"J Bone Miner Res"},{"key":"1595_CR6","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1038\/ng.845","volume":"43","author":"OM Albagha","year":"2011","unstructured":"Albagha OM, Wani SE, Visconti MR, Alonso N, Goodman K, Brandi ML, Cundy T, Chung PY, Dargie R, Devogelaer JP, Falchetti A, Fraser WD, Gennari L, Gianfrancesco F, Hooper MJ, Van Hul W, Isaia G, Nicholson GC, Nuti R, Papapoulos S, Montes Jdel P, Ratajczak T, Rea SL, Rendina D, Gonzalez-Sarmiento R, Di Stefano M, Ward LC, Walsh JP, Ralston SH, Genetic Determinants of Paget\u2019s Disease C (2011) Genome-wide association identifies three new susceptibility loci for Paget\u2019s disease of bone. Nat Genet 43:685\u2013689. https:\/\/doi.org\/10.1038\/ng.845","journal-title":"Nat Genet"},{"key":"1595_CR7","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/ng.562","volume":"42","author":"OM Albagha","year":"2010","unstructured":"Albagha OM, Visconti MR, Alonso N, Langston AL, Cundy T, Dargie R, Dunlop MG, Fraser WD, Hooper MJ, Isaia G, Nicholson GC, Del Pino MJ, Gonzalez-Sarmiento R, Di SM, Tenesa A, Walsh JP, Ralston SH (2010) Genome-wide association study identifies variants at CSF1, OPTN and TNFRSF11A as genetic risk factors for Paget\u2019s disease of bone. Nat Genet 42:520\u2013524","journal-title":"Nat Genet"},{"key":"1595_CR8","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1172\/JCI115584","volume":"89","author":"GD Roodman","year":"1992","unstructured":"Roodman GD, Kurihara N, Ohsaki Y, Kukita A, Hosking D, Demulder A, Smith JF, Singer FR (1992) Interleukin 6. A potential autocrine\/paracrine factor in Paget\u2019s disease of bone. J Clin Invest 89:46\u201352. https:\/\/doi.org\/10.1172\/JCI115584","journal-title":"J Clin Invest"},{"key":"1595_CR9","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/art.10834","volume":"48","author":"L Alvarez","year":"2003","unstructured":"Alvarez L, Peris P, Guanabens N, Vidal S, Ros I, Pons F, Filella X, Monegal A, Munoz-Gomez J, Ballesta AM (2003) Serum osteoprotegerin and its ligand in Paget\u2019s disease of bone: relationship to disease activity and effect of treatment with bisphosphonates. Arthritis Rheum 48:824\u2013828","journal-title":"Arthritis Rheum"},{"key":"1595_CR10","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1007\/s002239900254","volume":"60","author":"VM Natale","year":"1997","unstructured":"Natale VM, Filho WJ, Duarte AJ (1997) Cellular immunity aspects in elderly subjects with Paget\u2019s disease of bone. Calcif Tissue Int 60:410\u2013414","journal-title":"Calcif Tissue Int"},{"key":"1595_CR11","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/qjmed\/95.4.233","volume":"95","author":"SD Neale","year":"2002","unstructured":"Neale SD, Schulze E, Smith R, Athanasou NA (2002) The influence of serum cytokines and growth factors on osteoclast formation in Paget\u2019s disease. QJM 95:233\u2013240","journal-title":"QJM"},{"key":"1595_CR12","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1097\/j.pain.0000000000001260","volume":"159","author":"D Rendina","year":"2018","unstructured":"Rendina D, De Filippo G, Postiglione L, Covelli B, Ricciardone M, Guillaume S, Di Spigna G, Selleri C, Merlotti D, Bianciardi S, Materozzi M, Muscariello R, De Pascale F, D\u2019Elia L, Nuti R, Strazzullo P, Gennari L (2018) Interleukin-6 trans-signaling and pathological low back pain in patients with Paget disease of bone. Pain 159:1664\u20131673. https:\/\/doi.org\/10.1097\/j.pain.0000000000001260","journal-title":"Pain"},{"key":"1595_CR13","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.intimp.2013.12.003","volume":"18","author":"GR Werner de Castro","year":"2014","unstructured":"Werner de Castro GR, Buss Z, Da Rosa JS, Frode TS (2014) Inflammatory cytokines in Paget\u2019s disease of bone. Int Immunopharmacol 18:277\u2013281. https:\/\/doi.org\/10.1016\/j.intimp.2013.12.003","journal-title":"Int Immunopharmacol"},{"key":"1595_CR14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1359\/jbmr.090709","volume":"25","author":"AL Langston","year":"2010","unstructured":"Langston AL, Campbell MK, Fraser WD, MacLennan GS, Selby PL, Ralston SH (2010) Randomised trial of intensive bisphosphonate treatment versus symptomatic management in Paget\u2019s disease of bone. J Bone Miner Res 25:20\u201331. https:\/\/doi.org\/10.1359\/jbmr.090709","journal-title":"J Bone Miner Res"},{"key":"1595_CR15","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s00223-024-01279-0","volume":"115","author":"K Berg","year":"2025","unstructured":"Berg K, Dockrell D, Colvin L, Fraser WD, Tang JC, Aspray T, Dennison E, Divyateja H, Ghouri N, Hanison E, Keen R, McCloskey E, O\u2019Neill TW, Rahman F, Siddiqi M, Tuck S, Turton J, Ralston SH (2025) Causes of musculoskeletal pain in Paget\u2019s disease of bone. Calcif Tissue Int 115:533\u2013541. https:\/\/doi.org\/10.1007\/s00223-024-01279-0","journal-title":"Calcif Tissue Int"},{"key":"1595_CR16","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1093\/ije\/dys084","volume":"42","author":"BH Smith","year":"2013","unstructured":"Smith BH, Campbell A, Linksted P, Fitzpatrick B, Jackson C, Kerr SM, Deary IJ, Macintyre DJ, Campbell H, McGilchrist M, Hocking LJ, Wisely L, Ford I, Lindsay RS, Morton R, Palmer CN, Dominiczak AF, Porteous DJ, Morris AD (2013) Cohort profile: Generation Scotland: Scottish family health study (GS:SFHS). The study, its participants and their potential for genetic research on health and illness. Int J Epidemiol 42:689\u2013700. https:\/\/doi.org\/10.1093\/ije\/dys084","journal-title":"Int J Epidemiol"},{"key":"1595_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-47436-6","volume":"9","author":"SM Kerr","year":"2019","unstructured":"Kerr SM, Klaric L, Halachev M, Hayward C, Boutin TS, Meynert AM, Semple CA, Tuiskula AM, Swan H, Santoyo-Lopez J, Vitart V, Haley C, Dean J, Miedzybrodzka Z, Aitman TJ, Wilson JF (2019) An actionable KCNH2 long QT syndrome variant detected by sequence and haplotype analysis in a population research cohort. Sci Rep 9:10964. https:\/\/doi.org\/10.1038\/s41598-019-47436-6","journal-title":"Sci Rep"},{"key":"1595_CR18","doi-asserted-by":"publisher","first-page":"2121","DOI":"10.23889\/ijpds.v8i1.2121","volume":"8","author":"SM Kerr","year":"2023","unstructured":"Kerr SM, Edwards R, Buchanan D, Dean J, Miedzybrodzka Z, Wilson JF (2023) VIKING II, a worldwide observational cohort of volunteers with northern isles ancestry. Int J Popul Data Sci 8:2121. https:\/\/doi.org\/10.23889\/ijpds.v8i1.2121","journal-title":"Int J Popul Data Sci"},{"key":"1595_CR19","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1080\/01621459.1967.10500925","volume":"62","author":"D Quade","year":"1967","unstructured":"Quade D (1967) Rank analysis of covariance. J Am Stat Assoc 62:1187\u20131200","journal-title":"J Am Stat Assoc"},{"key":"1595_CR20","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a016295","volume":"6","author":"T Tanaka","year":"2014","unstructured":"Tanaka T, Narazaki M, Kishimoto T (2014) IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol 6:a016295. https:\/\/doi.org\/10.1101\/cshperspect.a016295","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"1595_CR21","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1146\/annurev.iy.08.040190.001345","volume":"8","author":"J Van Snick","year":"1990","unstructured":"Van Snick J (1990) Interleukin-6: an overview. Annu Rev Immunol 8:253\u2013278. https:\/\/doi.org\/10.1146\/annurev.iy.08.040190.001345","journal-title":"Annu Rev Immunol"},{"key":"1595_CR22","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1016\/0006-291x(89)90851-6","volume":"162","author":"CW Lowik","year":"1989","unstructured":"Lowik CW, van der Pluijm G, Bloys H, Hoekman K, Bijvoet OL, Aarden LA, Papapoulos SE (1989) Parathyroid hormone (PTH) and PTH-like protein (PLP) stimulate interleukin-6 production by osteogenic cells: a possible role of interleukin-6 in osteoclastogenesis. Biochem Biophys Res Commun 162:1546\u20131552. https:\/\/doi.org\/10.1016\/0006-291x(89)90851-6","journal-title":"Biochem Biophys Res Commun"},{"key":"1595_CR23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1007\/164_2019_346","volume":"262","author":"J Lorenzo","year":"2020","unstructured":"Lorenzo J (2020) Cytokines and bone: osteoimmunology. Handb Exp Pharmacol 262:177\u2013230. https:\/\/doi.org\/10.1007\/164_2019_346","journal-title":"Handb Exp Pharmacol"},{"key":"1595_CR24","doi-asserted-by":"publisher","first-page":"4683","DOI":"10.1210\/endo.140.10.7036","volume":"140","author":"A Grey","year":"1999","unstructured":"Grey A, Mitnick MA, Masiukiewicz U, Sun BH, Rudikoff S, Jilka RL, Manolagas SC, Insogna K (1999) A role for interleukin-6 in parathyroid hormone-induced bone resorption in vivo. Endocrinology 140:4683\u20134690. https:\/\/doi.org\/10.1210\/endo.140.10.7036","journal-title":"Endocrinology"},{"key":"1595_CR25","doi-asserted-by":"publisher","first-page":"E784","DOI":"10.1152\/ajpendo.00029.2005","volume":"289","author":"CA O\u2019Brien","year":"2005","unstructured":"O\u2019Brien CA, Jilka RL, Fu Q, Stewart S, Weinstein RS, Manolagas SC (2005) IL-6 is not required for parathyroid hormone stimulation of RANKL expression, osteoclast formation, and bone loss in mice. Am J Physiol Endocrinol Metab 289:E784\u2013E793","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"1595_CR26","doi-asserted-by":"publisher","first-page":"11924","DOI":"10.1073\/pnas.90.24.11924","volume":"90","author":"T Tamura","year":"1993","unstructured":"Tamura T, Udagawa N, Takahashi N, Miyaura C, Tanaka S, Yamada Y, Koishihara Y, Ohsugi Y, Kumaki K, Taga T (1993) Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci U S A 90:11924\u201311928","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1595_CR27","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s12974-016-0607-6","volume":"13","author":"YQ Zhou","year":"2016","unstructured":"Zhou YQ, Liu Z, Liu ZH, Chen SP, Li M, Shahveranov A, Ye DW, Tian YK (2016) Interleukin-6: an emerging regulator of pathological pain. J Neuroinflammation 13:141. https:\/\/doi.org\/10.1186\/s12974-016-0607-6","journal-title":"J Neuroinflammation"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-026-01595-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-026-01595-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-026-01595-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:45:29Z","timestamp":1788371129000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-026-01595-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,2]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1595"],"URL":"https:\/\/doi.org\/10.1007\/s00223-026-01595-7","relation":{},"ISSN":["1432-0827"],"issn-type":[{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,2]]},"assertion":[{"value":"7 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Prof Stuart Ralston declares that his institution is in receipt of consultancy fees from UCB, Ascendis Pharma, Angitia Biopharmaceuticals and Relation Therapeutics outside the submitted work. The other authors declare that they have no conflicts of interest.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Pain in Paget\u2019s (PIP) study was approved by the West of Scotland Research Ethics Committee 3 (18\/WS\/0236). The Paget\u2019s disease: randomized trial of intensive versus symptomatic management (PRISM) Trial was approved by the UK Multicentre Research Ethics Committee for Scotland (MREC01\/0\/53) and by the Medicines & Healthcare Products Regulatory Authority (CTA21583\/0002\/001\u20130001). Generation Scotland gained ethical approval from NHS Tayside Research Ethics Committee (REC reference number 05\/S1401\/89). The Viking Genes study was approved by the South-East Scotland Research Ethics Committee (12\/SS\/015).","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all patients included in the study.","order":3,"name":"Ethics","label":"Informed Consent","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"134"}}